ESMO Breast 2025 | Upcoming trials assessing ADCs in HER2+ breast cancer in 2024
Pavani Chalasani, MD, MPH, The George Washington University, Washington, DC, comments on the upcoming results of the DESTINY-Breast09 study (NCT04784715), of trastuzumab deruxtecan (T-DXd) plus pertuzumab in first-line treatment for HER2+ breast cancer. With the advent of multiple antibody-drug conjugates (ADCs), clinicians need into elucidate the optimal sequencing strategy, as well as their potential pairing with CDK4/6 inhibitors. This knowledge could lead to enhanced responses and prolonged remission in this group of patients. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
